Search results
Results from the WOW.Com Content Network
bedinvetmab - nerve growth factor inhibitor monoclonal antibody used for osteoarthritis in dogs; benazepril – ACE-inhibitor used in heart failure, hypertension, chronic kidney failure and protein-losing nephropathy; bethanechol – stimulates bladder contractions, tranquilizer, makes the patient feel no pain; bexagliflozin - oral antidiabetic ...
Capromorelin, sold under the brand names Entyce and Elura, is a medication used for the management of weight loss in cats and dogs. [5] [6] Capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain. [2] Capromorelin was developed by Pfizer. [7] [8] Capromorelin was approved for veterinary use in the United States in ...
This gene encodes a protein that is a transmembrane receptor for growth hormone. [10] [11] Binding of growth hormone to the receptor leads to reorientation of a pre-assembled receptor dimer dimerization (the receptor may however also exist as monomers on the cell surface [12]) and the activation of an intra- and intercellular signal transduction pathway leading to growth. [13]
Growth hormone secreting pituitary tumours in dogs have only been observed in male dogs of large breeds. Excessive growth hormone secretion caused by progestone use has been seen in a variety of breeds of varying size, as well as in mixed breed dogs , the same is true of growth hormone excess brought on by the oestrous cycle.
Examorelin (developmental code names EP-23905, MF-6003), also known as hexarelin, is a potent, synthetic, peptidic, orally-active, centrally-penetrant, and highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and a growth hormone secretagogue which was developed by Mediolanum Farmaceutici.
Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. [1] [2] [3] It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. [4]
Gonadotropin-releasing hormone antagonists (GnRH antagonists) are a class of medications that antagonize the gonadotropin-releasing hormone receptor (GnRH receptor) and thus the action of gonadotropin-releasing hormone (GnRH).
Gonadorelin is the generic name of the drug and its INN Tooltip International Nonproprietary Name, BAN Tooltip British Approved Name, and JAN Tooltip Japanese Accepted Name, while gonadorelina is its DCIT Tooltip Denominazione Comune Italiana and gonadoréline is its DCF Tooltip Dénomination Commune Française.